ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KIT-inhibitor-ATP-competitive
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KIT-inhibitor-ATP-competitive
4
trial(s) found.
NCT05327686
Radonc
Phase 2
Recruiting
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (
SAMURAI
)
radiotherapy
+ KIT inhibitor,ATP-competitive
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04996875
Haem
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (
2024-511407-42-00--CGT9486-20-201
)
KIT D816V inhibitor
KIT inhibitor,type 1
+ KIT inhibitor,ATP-competitive
Haematological malignancy
Mast cell leukaemia
Systemic mastocytosis
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
QLD
4215 - Southport - Gold Coast University Hospital
NCT05805501
Advanced
Phase 2
paused
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (
BO43936
)
KIT inhibitor,ATP-competitive
VEGFR/PDGFR inhibitor
Clear cell renal cell carcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12616001187437
Advanced
Phase 2
Not recruiting
Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing. (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,first generation
ALK inhibitor,second generation
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,first generation
BCR-ABL1 inhibitor,second generation
Bortezomib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Cabozantinib
Ceritinib
Crizotinib
Dasatinib
EGFR inhibitor
EGFR inhibitor,first generation
EGFR inhibitor,type II
ERBB2 inhibitor
ERBB2 inhibitor,first generation
Erlotinib
Everolimus
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
FLT3 inhibitor
Gefitinib
HDAC inhibitor
IGF1R inhibitor
Imatinib
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,ATP-competitive
KIT inhibitor,first generation
Lapatinib
MEK inhibitor
MET inhibitor
MET inhibitor,type 1
MET inhibitor,type 2
Nilotinib
Olaparib
PARP inhibitor
PDGFRA inhibitor
PDGFR inhibitor
Palbociclib
Pazopanib
RAF inhibitor
RET inhibitor
ROS1 inhibitor
Ramucirumab
Regorafenib
SRC inhibitor
Sorafenib
Sunitinib
Trametinib
VEGFR2 inhibitor
VEGFR inhibitor
Vorinostat
YES1 inhibitor
anti-VEGFR2 monoclonal antibody
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,AXL-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,ERBB2-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,FLT3-targeting
cancer therapy,HDAC-targeting
cancer therapy,IGF1R-targeting
cancer therapy,KIT-targeting
cancer therapy,MEK-targeting
cancer therapy,MET-targeting
cancer therapy,PARP-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,RAF-targeting
cancer therapy,RET-targeting
cancer therapy,ROS1-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,VEGFR2-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,proteasome-targeting
immuno-oncology therapy,VEGFR2-targeting
mTORC1 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
proteasome inhibitor
+ KIT inhibitor,ATP-competitive
Melanoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
paused (1)
Not recruiting (1)
Recruitment Country and State
VIC (2)
NSW (2)
QLD (2)
Phase
Phase 2 (4)
Trial Type
Advanced (2)
Radonc (1)
Haem (1)
Cancer Therapy Class
KIT
100%
PDGFR
75%
VEGFR
75%
AXL
50%
MET
50%
PD-1
50%
PD-1/PD-L1
50%
RET
50%
ROS1
50%
VEGFR2
50%
CTLA4
25%
PD-L1
25%
VEGF
25%
LAG3
25%
TIGIT
25%
ALK
25%
BCR-ABL1
25%
CDK4
25%
CDK6
25%
CRAF
25%
EGFR
25%
ERBB2
25%
FGFR1
25%
FGFR1/2/3
25%
FGFR2
25%
FGFR3
25%
FGFR4
25%
FLT3
25%
HDAC
25%
IGF1R
25%
MEK
25%
PARP
25%
PDGFRA
25%
RAF
25%
SRC
25%
YES1
25%
mTOR
25%
mTORC1
25%
proteasome
25%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
Cancer Type
Cancer
Solid tumour
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Haematological malignancy
Mast cell disorder
Mast cell leukaemia
Systemic mastocytosis
Melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy